Cornelis Erik Hack

Title: Cornelis Erik Hack: Innovator in Fusion Protein Technology

Introduction

Cornelis Erik Hack is a notable inventor based in Diemen, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins. With a total of 11 patents to his name, Hack's work focuses on innovative solutions for medical conditions.

Latest Patents

One of Hack's latest patents involves a fusion protein comprising interleukin 13 and a regulatory cytokine. This invention includes various interleukins such as interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13. The patent also covers a nucleic acid molecule encoding this fusion protein, a vector containing the nucleic acid molecule, and a host cell that incorporates the nucleic acid or vector. Furthermore, the invention outlines a method for producing the fusion protein. This fusion protein or a gene therapy vector encoding it may be utilized in the prevention or treatment of conditions characterized by pathological pain, chronic pain, neuro-inflammation, and neurodegeneration.

Career Highlights

Throughout his career, Cornelis Erik Hack has worked with various companies, including Synerkine Pharma B.V. and Broteio Pharma B.V. His expertise in biotechnology has allowed him to contribute to advancements in medical treatments and therapies.

Collaborations

Some of Hack's notable coworkers include Cafer Yildiz and Willem Theodoor Hermens. Their collaborative efforts have further enhanced the impact of their research and innovations in the field.

Conclusion

Cornelis Erik Hack is a distinguished inventor whose work in fusion protein technology has the potential to revolutionize treatments for various medical conditions. His contributions to biotechnology continue to pave the way for future innovations.